Study Title: Phase Ib dose de-escalation study of the PI3K alpha/delta inhibitor, Copanlisib given in combination with the immunotherapeutic agents, Nivolumab and Rituximab in patients with relapsed/refractory indolent lymphoma. Big Ten Cancer Research Consortium BTCRC-LYM17-145
 

• Open to Accrual at:
  • University of Michigan Rogel Cancer Center
  • Fred & Pamela Buffett Cancer Center (University of Nebraska)
  • Rutgers Cancer Institute of New Jersey
• Closed to Accrual at: 
  • University of Illinois Cancer Center
• Learn more:
  • clinicaltrials.gov: NCT04431635
  • Big Ten CRC News Release

Study Contact: studies@hoosiercancer.org; (317) 921-2050.